Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel, Israel.
Translational Research Lab, Assuta Medical Centers, Tel-Aviv, Israel.
Cancer Med. 2023 Apr;12(7):8199-8210. doi: 10.1002/cam4.5621. Epub 2023 Jan 24.
Noncoding RNAs such as microRNAs (miRNAs) have attracted attention as biological pathway regulators, which differ from chromosomal translocations and gene point mutations. Their involvement in the molecular mechanisms underlying light chain (AL) amyloidosis pathogenesis is yet to be elucidated.
To decipher specific miRNA expression profile in AL-amyloidosis and to examine how miRNAs are involved in AL pathogenesis.
The expression profile of miRNAs and mRNA from bone marrow (BM)-derived CD138+ cells were determined using the NanoString nCounter assay and RNA-Seq, respectively. The effect of aberrantly expressed miRNAs on potential molecular targets was analyzed by qRT-PCR, Western blot, Mito-potential assay, and Annexin-PI staining.
Genes which were significantly differentially expressed between AL-amyloidosis and MM, were found to be involved in cell growth and apoptotic mechanisms. Specifically, BCL2L1, MCL1, and BCL2 were upregulated in AL-amyloidosis compared with MM and controls. The levels of miR-181a-5p and miR-9-5p, which regulate the above-mentioned genes, were lower in BM samples from AL-amyloidosis compared with controls, providing a mechanism for BCL2 family gene upregulation. When miR-9-5p and miR-181a-5p were overexpressed in ALMC1 cells, BCL2L1, MCL1, and BCL2 were downregulated and induced apoptosis. Treatment of ALMC-1 cells with venetoclax, (BCL-2 inhibitor), resulted in the upregulation of those miRNAs, the downregulation of BCL2, MCL1, and BCL2L1 mRNA and protein levels, and subsequent apoptosis.
Our findings suggest that miR-9-5p and miR-181a-5p act as tumor-suppressors whose downregulation induces anti-apoptotic mechanisms underlying the pathogenesis of AL-amyloidosis. The study highlights the post-transcriptional regulation in AL-amyloidosis and provides pathogenetic evidence for the potential use of BCL-2 inhibitors in this disease.
非编码 RNA 如 microRNAs(miRNAs)作为生物途径调节剂引起了关注,它们与染色体易位和基因突变不同。它们在轻链(AL)淀粉样变性发病机制的分子机制中的参与尚未阐明。
破译 AL 淀粉样变性中特定 miRNA 的表达谱,并研究 miRNA 如何参与 AL 发病机制。
使用 NanoString nCounter 测定法和 RNA-Seq 分别确定来自骨髓(BM)衍生的 CD138+细胞的 miRNA 和 mRNA 的表达谱。通过 qRT-PCR、Western blot、Mito 潜能测定和 Annexin-PI 染色分析异常表达的 miRNA 对潜在分子靶标的影响。
在 AL 淀粉样变性和 MM 之间差异表达的基因被发现参与细胞生长和凋亡机制。具体而言,与 MM 和对照相比,AL 淀粉样变性中 BCL2L1、MCL1 和 BCL2 上调。与对照相比,来自 AL 淀粉样变性 BM 样本中的 miR-181a-5p 和 miR-9-5p 水平较低,这调节了上述基因,为 BCL2 家族基因上调提供了一种机制。当在 ALMC1 细胞中过表达 miR-9-5p 和 miR-181a-5p 时,BCL2L1、MCL1 和 BCL2 下调并诱导凋亡。用 venetoclax(BCL-2 抑制剂)处理 ALMC-1 细胞导致这些 miRNA 的上调、BCL2、MCL1 和 BCL2L1 mRNA 和蛋白水平的下调以及随后的凋亡。
我们的研究结果表明,miR-9-5p 和 miR-181a-5p 作为肿瘤抑制因子发挥作用,其下调诱导 AL 淀粉样变性发病机制中的抗凋亡机制。该研究强调了 AL 淀粉样变性中的转录后调控,并为 BCL-2 抑制剂在该疾病中的潜在应用提供了发病机制证据。